Education and debate

Oxygen treatment for acute severe asthma

David Inwald, MRC clinical training fellow ^a, Mark Roland, clinical research fellow ^b, Lieske Kuitert, consultant in respiratory medicine ^c, Sheila A McKenzie, consultant in paediatric respiratory medicine ^d, Andy Petros, consultant in paediatric intensive care medicine ^e. 

^a Portex Department of Anaesthesia, Intensive Care and Respiratory Medicine, Institute of Child Health, London WC1N 1EH, ^b Department of Respiratory Medicine, St Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1A 7BE, ^c Royal London Hospital, London E1 1BB, ^d Queen Elizabeth Children's Service, Royal London Hospital, London E1 1BB, ^e Paediatric Intensive Care Unit, Great Ormond Street Hospital, London WC1N 3JF

Correspondence to: D Inwald D.Inwald{at}ich.ucl.ac.uk

Deaths from asthma in England and Wales dropped by about 6% a year in people aged 5-64 from 1983 to 1995,¹ but about 20 children and 1600 adults still die in the United Kingdom every year from acute asthma. Profound hypoxaemia may be a readily preventable cause of some of these deaths. The British Thoracic Society's asthma guidelines advise oxygen as first line treatment in hospital for all patients in cases of acute severe asthma.² However, the guidelines do not advise treatment with oxygen in primary care in children and do not insist on its use in adults. The recent death of a child in a primary care setting after administration of salbutamol nebulised with air prompted us to question whether treatment with oxygen should be recommended in all cases of acute severe asthma, including those presenting in primary care.

	Methods

A systematic review was not possible as there have never been any randomised controlled trials of oxygen in acute severe asthma. We therefore present a traditional literature review and our opinion based on it. We selected 24 publications from our personal collections and from Medline searches. Using the search terms "asthma" and "hypoxaemia or hypoxemia or hypoxia or oxygen" and "salbutamol or albuterol" yielded 204 papers, of which 11 were included in this review. The other 13 papers that we evaluated were from our personal collections.

	Results and discussion

In acute severe asthma, narrowing of the airway occurs as a result of bronchospasm, mucosal oedema, and hypersecretion. The homoeostatic response to this is to decrease blood flow to underventilated lung units, thus maximising oxygenation by matching pulmonary perfusion with alveolar ventilation. This was shown in an elegant series of studies spanning nearly two decades that used the multiple inert gas technique to study ventilation-perfusion relations and gas exchange in asthmatic patients with varying degrees of disease severity.^3-5 The pattern of ventilation-perfusion is bimodal in acute severe asthma, ranging from normally perfused areas to areas of hypoxic pulmonary vasoconstriction. However, the percentage of cardiac output to areas with a low ventilation-perfusion ratio increases with worsening severity of the acute flare, ranging from 0.4% in chronic stable asthma to 28-36% in the most severe acute flares, ^{5 6} including those requiring mechanical ventilation.

Treatment with inhaled ₂ agonists is often given to relieve bronchospasm and improve oxygenation. In acute severe asthma, nebulisation of ₂ agonists without oxygen can cause or worsen hypoxaemia. The mechanism for this has been understood since 1967, when it was shown that isoprenaline, a  agonist then in common use for asthma, when nebulised with compressed air resulted in pulmonary vasodilatation, increasing perfusion to poorly ventilated lung units and ventilation-perfusion mismatch, and thus worsening hypoxaemia.⁷ Since then it has been found that salbutamol can also worsen ventilation-perfusion mismatch by causing pulmonary vasodilatation and increasing cardiac output.⁸

Findings in children
The first report of such effects in children was in 1969, when a significant fall in arterial blood oxygen saturation was found in asthmatic children after they inhaled salbutamol, even though this improved forced expiratory volume in one second in the same period.⁹ A later study recorded a fall in arterial oxygen saturation of more than 5% in nine out of 18 asthmatic children aged 2-15 years who were treated with salbutamol nebulised with air.¹⁰ A small randomised crossover study failed to show a significant decrease in oxygenation during nebulisation with air in 27 episodes of acute severe asthma; however, in 10 cases arterial oxygen saturation decreased by 2-6%, with the biggest drops occurring 10-15 minutes after nebulisation.¹¹ More recently, in a study of 111 children with acute severe asthma, six children with pneumonic consolidation in addition to asthma who were treated with salbutamol nebulised with oxygen became profoundly hypoxaemic when oxygen was discontinued after nebulisation.¹² Taken together, these studies provide strong evidence that a small number of children develop important hypoxaemia related to salbutamol administration during acute episodes of asthma if the drug is administered without oxygen.

Findings in adults
The findings in children contrast with those in adults. Over the past 30 years many studies have assessed the effects of salbutamol on oxygenation in asthmatic adults, either as a primary or secondary end point. ^{3 8 13-18} Most of these studies were small, uncontrolled, and of widely varying design, and some had conflicting results. Most published data show that salbutamol does not have a clinically important effect on oxygenation in asthmatic adults. This seems to be true for both stable and acute asthma, across a range of doses administered by various routes. However, the studies are limited by their exclusion of the most severe exacerbations, particularly those accompanied by marked hypoxaemia.¹⁸ Even though the average change in oxygenation in response to salbutamol in these studies may not be significant, the fact that considerable variability exists among patients has ramifications for those in extremis. In 1974 Choo-Kang postulated that this variability might be due to variations between patients in the response of vascular smooth muscle to stimulation of ₂ adrenoceptors,¹⁸ and it is now known that polymorphism of the ₂ adrenoceptor gene is an important inheritable determinant of smooth muscle response to agonists in the airway.¹⁹

Deaths from asthma
Most asthma deaths occur in the community, often in patients whose symptoms have been poorly controlled for days or even weeks before the fatal attack.²⁰ Two hypotheses have been postulated for the cause of these deaths. Firstly, cardiac arrhythmias may contribute to some of the observed mortality, particularly in adults. The risk of arrhythmia is theoretically greatly increased by hypokalaemia and prolongation of the QTc interval, both well described side effects of ₂ agonists and theophyllines.²¹ However, in a series of admissions of patients whose asthma attacks were nearly fatal, few arrhythmias other than sinus tachycardias and bradycardias were documented.²²

Caveats
There are two important caveats to our suggestion. Firstly, whether oxygen should be available for home visits requires careful consideration, including a risk-benefit analysis. This would be best done by the British Thoracic Society in conjunction with primary care colleagues when the guidelines are next updated. Secondly, administration of oxygen is clearly beneficial in children and young adults with asthma; however, patients over 45 with a history of chronic obstructive pulmonary disease should receive salbutamol nebulised with air to avoid carbon dioxide narcosis.

	Conclusion

Treatment of mild and moderate asthma attacks should continue as at present, with either air driven nebulisers or metered dose inhalers and holding chambers. This should not cause hypoxaemia. However, if the signs of a severe or life threatening attack are present (see box), oxygen before and after treatment with a ₂ agonist nebulised with oxygen should be the standard treatment wherever the patient happens to be. We urge the British Thoracic Society to review this issue when it updates its guidelines.

	Acknowledgments

   Contributors: DI and AJP conceived the idea for the paper. All authors discussed the core ideas and contributed to the writing and editing of the paper. DI is guarantor.

	Footnotes

Funding: DI is funded by the Medical Research Council.

Competing interests: None declared.

	References

1.	Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ 1997; 314: 1439-1441[Abstract/Free Full Text].
2.	The British Guidelines on Asthma Management 1995 review and position statement. Thorax 1997; 52(suppl 1): S1-20[Free Full Text].
3.	Ballester E, Reyes A, Roca J, Guitart R, Wagner PD, Rodriguez R. Ventilation-perfusion mismatching in acute severe asthma: effects of salbutamol and 100% oxygen. Thorax 1989; 44: 258-267[Abstract].
4.	Wagner PD, Dantzker DR, Iacovoni VE, Tomlin WC, West JB. Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis 1978; 118: 511-524[Medline].
5.	Rodriguez-Roisin R, Ballester E, Roca J, Torres A, Wagner PD. Mechanisms of hypoxemia in patients with status asthmaticus requiring mechanical ventilation. Am Rev Respir Dis 1989; 139: 732-739[Medline].
6.	Ballester E, Roca J, Ramis L, Wagner PD, Rodriguez-Roisin R. Pulmonary gas exchange in severe chronic asthma. Response to 100% oxygen and salbutamol. Am Rev Respir Dis 1990; 141: 558-562[Medline].
7.	Field GB. The effects of posture, oxygen, isoproterenol and atropine on ventilation-perfusion relationships in the lung in asthma. Clin Sci 1967; 32: 279-288[Medline].
8.	Harris L. Comparison of the effect on blood gases, ventilation, and perfusion of isoproterenol-phenylephrine and salbutamol aerosols in chronic bronchitis with asthma. J Allergy Clin Immunol 1972; 49: 63-71[CrossRef][Medline].
9.	Bass BH, Disney ME, Morrison SJ. Effect of salbutamol on respiratory function in children with asthma. Lancet 1969; 2: 438[Medline].
10.	Tal A, Pasterkamp H, Leahy F. Arterial oxygen desaturation following salbutamol inhalation in acute asthma. Chest 1984; 86: 868-869[Abstract/Free Full Text].
11.	Gleeson JG, Green S, Price JF. Air or oxygen as driving gas for nebulised salbutamol. Arch Dis Child 1988; 63: 900-904[Abstract].
12.	Connett G, Lenney W. Prolonged hypoxaemia after nebulised salbutamol. Thorax 1993; 48: 574-575[Abstract].
13.	Palmer KN, Diament ML. Effect of salbutamol on spirometry and blood-gas tensions in bronchial asthma. BMJ 1969; i: 31-32.
14.	Gunawardena KA, Patel B, Campbell IA, MacDonald JB, Smith AP. Oxygen as a driving gas for nebulisers: safe or dangerous? BMJ 1984; 288: 272-274.
15.	Douglas JG, Rafferty P, Fergusson RJ, Prescott RJ, Crompton GK, Grant IW, et al. Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe? Thorax 1985; 40: 180-183[Abstract].
16.	Williams AJ, Weiner C, Reiff D, Swenson ER, Fuller RW, Hughes JM. Comparison of the effect of inhaled selective and non-selective adrenergic agonists on cardiorespiratory parameters in chronic stable asthma. Pulm Pharmacol 1994; 7: 235-241[CrossRef][Medline].
17.	Alliott RJ, Lang BD, Rawson DR, Leckie WJ. Effects of salbutamol and isoprenaline-phenylephrine in reversible airways obstruction. BMJ 1972; 1: 539-542.
18.	Choo-Kang YF, Tribe AE, Grant IW. Salbutamol by intermittent positive pressure ventilation in status asthmaticus. Scott Med J 1974; 19: 191-195[Medline].
19.	Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 1999; 36: 583-590[Medline].
20.	Somerville M, Williams EM, Pearson MG. Asthma deaths in Mersey region 1989-1990. J Public Health Med 1995; 17: 397-403[Abstract/Free Full Text].
21.	Crane J, Burgess CD, Graham AN, Maling TJ. Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease. N Z Med J 1987; 100: 309-311[Medline].
22.	Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324: 285-288[Abstract].
23.	McFadden ERJ, Lyons HA. Arterial-blood gas tension in asthma. N Engl J Med 1968; 278: 1027-1032.
24.	Cates CJ, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2000; (2): CD000052.

(Accepted 8 March 2001)